Company Filing History:
Years Active: 2016-2024
Title: **Innovator Spotlight: Jason C O'Neill of Amgen Inc.**
Introduction
Jason C O'Neill is an accomplished inventor based in Brier, Washington, known for his significant contributions to the field of biomedicine. With a focused expertise in antigen binding proteins, O'Neill holds two patents related to the human IL-23 protein, reflecting his commitment to advancing therapeutic options for various health conditions.
Latest Patents
O'Neill's latest innovations revolve around **Human IL-23 antigen binding proteins**. These patents detail antigen binding proteins that specifically bind to the human IL-23 protein. Additionally, the patents include information on nucleic acids encoding the antigen binding proteins, vectors, and cells involved in this engagement. Importantly, the patents address the diagnostic and therapeutic applications of IL-23 antigen binding proteins, showcasing O'Neill's focus on developing practical solutions for healthcare challenges.
Career Highlights
Jason is currently employed by **Amgen Inc.**, a leading biotechnology company dedicated to discovering, developing, and delivering innovative human therapeutics. His role involves extensive research and development work aimed at enhancing patient treatment methodologies. O'Neill is part of a talented team committed to pushing the boundaries of biomedical science.
Collaborations
Throughout his career, Jason has collaborated with notable colleagues, including Jennifer E Towne and Yu Zhang. These collaborations have fostered a productive environment where innovative ideas can flourish, contributing meaningfully to the advancements in their shared field.
Conclusion
Jason C O'Neill stands out as an influential figure in biotechnology, exemplifying the spirit of innovation through his patents and collaborations at Amgen Inc. His work on human IL-23 antigen binding proteins not only illustrates his scientific acumen but also highlights the potential for significant advancements in diagnostic and therapeutic realms. As he continues his journey, O'Neill remains a pivotal player in the quest for groundbreaking healthcare solutions.